Aethlon Medical Gestion

Gestion contrôle des critères 4/4

Le PDG Aethlon Medical est Jim Frakes, nommé en Jan2008, a un mandat de 16.83 ans. La rémunération annuelle totale est $ 416.45K, composée du salaire de 100% et des bonus 0%, y compris les actions et options de la société. détient directement 0.017% des actions de la société, d'une valeur de € 887.61. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.8 ans et 7 ans.

Informations clés

Jim Frakes

Directeur général

US$416.4k

Rémunération totale

Pourcentage du salaire du PDG	100.0%
Durée du mandat du directeur général	16.8yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	3.8yrs
Durée moyenne du mandat des membres du conseil d'administration	7yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Jim Frakes a-t-elle évolué par rapport aux bénéfices de Aethlon Medical?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$11m
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	US$416k	US$416k	-US$12m
Dec 31 2023	n/a	n/a	-US$12m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	n/a	n/a	-US$13m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	n/a	n/a	-US$9m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$9m
Mar 31 2021	US$582k	US$275k	-US$8m
Dec 31 2020	n/a	n/a	-US$7m
Sep 30 2020	n/a	n/a	-US$6m
Jun 30 2020	n/a	n/a	-US$6m
Mar 31 2020	US$355k	US$264k	-US$6m
Dec 31 2019	n/a	n/a	-US$6m
Sep 30 2019	n/a	n/a	-US$7m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	US$286k	US$256k	-US$6m
Dec 31 2018	n/a	n/a	-US$6m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	US$235k	US$235k	-US$6m

Rémunération vs marché: La rémunération totale de Jim ($USD 416.45K ) est dans la moyenne des entreprises de taille similaire sur le marché German ($USD 476.59K ).

Rémunération et revenus: La rémunération de Jim a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Jim Frakes (67 yo)

16.8yrs

Titularisation

US$416,449

Compensation

Mr. James B. Frakes, also known as Jim, M.B.A. has been the Chief Financial Officer at Aethlon Medical, Inc. since January 2008 and served as its Interim Chief Executive Officer since November 07, 2023 unt...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
James Frakes	CEO, CFO	16.8yrs	US$416.45k	0.017% € 887.6
Guy Cipriani	Senior VP & COO	less than a year	US$378.06k	0.013% € 670.9
Steven LaRosa	Chief Medical Officer	3.8yrs	US$430.00k	0% € 0

3.8yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Gestion expérimentée: L'équipe de direction de EJU0 est considérée comme expérimentée (ancienneté moyenne 3.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
James Frakes	CEO, CFO	less than a year	US$416.45k	0.017% € 887.6
Edward Broenniman	Independent Chairman of the Board	25.7yrs	US$147.50k	0.18% € 9.6k
Nathan Levin	Member of Extracorporeal Therapy Advisory Board	no data	pas de données	pas de données
Gregory T. Kovacs	Member of Extracorporeal Therapy Advisory Board	no data	pas de données	pas de données
Claudio Ronco	Member of Extracorporeal Therapy Advisory Board	no data	pas de données	pas de données
Larry Cowgill	Member of Sepsis & Inflammation Advisory Board	no data	pas de données	pas de données
John Kellum	Member of Extracorporeal Therapy Advisory Board	no data	pas de données	pas de données
Chetan Shah	Independent Director	11.4yrs	US$113.75k	0.15% € 8.1k
David Ward	Member of Extracorporeal Therapy Advisory Board	no data	pas de données	pas de données
Irshad Chaudry	Member of Sepsis & Inflammation Advisory Board	no data	pas de données	pas de données
Geert Schmid-Schönbein	Member of Sepsis & Inflammation Advisory Board	no data	pas de données	pas de données
Angela Rossetti	Independent Director	2.6yrs	US$113.00k	0.18% € 9.4k

7.0yrs

Durée moyenne de l'emploi

69yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de EJU0 sont considérés comme expérimentés (ancienneté moyenne 7 ans).

Aethlon Medical Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Insufficient new directors

Recent updates

New major risk - Revenue and earnings growth

Aethlon Medical Announces Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia

Aethlon Medical, Inc. to Report Q2, 2025 Results on Nov 13, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical, Inc. Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Extracellular Vesicles and MicroRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Donor Kidneys

Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024

Aethlon Medical, Inc. Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial

Aethlon Medical, Inc. to Report Q1, 2025 Results on Aug 14, 2024

Aethlon Medical, Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

New major risk - Shareholder dilution

Aethlon Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.69235 million.

Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma

Aethlon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $16.32 million.

Aethlon Medical, Inc. to Report Q3, 2024 Results on Feb 14, 2024

New major risk - Financial position

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology

Aethlon Medical, Inc. to Report Q1, 2024 Results on Aug 10, 2023

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

New major risk - Shareholder dilution

Full year 2023 earnings released: US$0.59 loss per share (vs US$0.71 loss in FY 2022)

Aethlon Medical, Inc. to Report Q4, 2023 Results on Jun 28, 2023

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)

Aethlon Medical, Inc. to Report Q3, 2023 Results on Feb 13, 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

First half 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 1H 2022)

Aethlon Medical, Inc. to Report Q2, 2023 Results on Nov 14, 2022

Aethlon Medical Receives Non-Compliance Notice of Delisting from Nasdaq

Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier

Forecast to breakeven in 2023

Aethlon Medical, Inc. to Report Q1, 2023 Results on Aug 09, 2022

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Aethlon Medical, Inc. Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

Aethlon Medical, Inc. to Report Fiscal Year 2022 Results on Jun 28, 2022

Insufficient new directors

Aethlon Medical, Inc. Announces Executive Changes

Aethlon Medical, Inc. to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

Full year 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in FY 2020)

Aethlon Medical, Inc. Publishes Case Studies of Two Critically ill Covid-19 Patients Treated with the Hemopurifier®

Forecast to breakeven in 2023

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2020)

Revenue beats expectations

New 90-day high: €2.30

Aethlon Medical, Inc. to Report Q3, 2021 Results on Feb 10, 2021

Aethlon Medical, Inc. Announces Executive Appointments

New 90-day high: €2.10

Aethlon Medical, Inc. Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer

New 90-day high: €1.94

New 90-day high: €1.49

Aethlon Medical, Inc. Announces Board Changes, Effective as of October 30, 2020

Aethlon Medical, Inc. Announces Executive Changes, Effective as of October 30, 2020

Aethlon Medical, Inc. to Report Q2, 2021 Results on Oct 28, 2020

New 90-day low - €1.11

First quarter earnings released

Aethlon Medical, Inc. to Report Q1, 2021 Results on Aug 11, 2020

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction